Previous Article in Journal
A (2-(Pyrrolidin-1-yl)ethan-1-olate)(1-oxo-3-phenyl-1,4-dihydronaphthalen-2-olate) μ-Oxo-Bridged Dicopper(II) Dimeric Complex
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

Methyl and Benzyl (Ethyl 3,4-di-O-benzyl-2-O-benzoyl-1-thio-β-d-glucopyranosyl)uronate

Centre for Glycoscience and School of Chemical and Physical Sciences, Keele University, Keele, Newcastle ST5 5BG, UK
*
Author to whom correspondence should be addressed.
Molbank 2024, 2024(3), M1847; https://doi.org/10.3390/M1847 (registering DOI)
Submission received: 20 June 2024 / Revised: 3 July 2024 / Accepted: 5 July 2024 / Published: 9 July 2024
(This article belongs to the Section Organic Synthesis)

Abstract

:
Methyl and benzyl (ethyl 3,4-di-O-benzyl-2-O-benzoyl-1-thio-β-D-glucopyranosyl)uronate were synthesised from a protected thioglycoside in three steps. A regioselective ring opening of the benzylidene acetal with BH3.THF generated C6-OH material, which was subsequently oxidised using biphasic TEMPO/BAIB conditions. The resultant uronic acid was esterified with either a methyl or benzyl moiety. The products were obtained on a multigram scale and fully characterised by 1H, 13C and 2D NMR, alongside MS and IR analysis.

Graphical Abstract

1. Introduction

Polysaccharides containing uronic acid moieties are prevalent in nature and display a multitude of physical properties and biological functions. Glycosaminoglycans (GAGs) are exemplars, in which glucuronic acid (GlcA) is a core building block in the repeating disaccharide units of heparin/heparan sulphate, chondroitin sulphate and hyaluronic acid [1]. Glycosaminoglycans are a family of linear heteropolysaccharides that are expressed ubiquitously on the cell surface and extracellular matrix [2]. They interact with growth factors, cytokines, chemokines and adhesion molecules, which play critical roles in cell division, gene expression, angiogenesis, inflammation and wound healing [3]. As part of a research programme targeting the synthesis of structurally defined glycosaminoglycans and related mimetic oligosaccharides [4,5,6,7,8], we required access to suitably protected GlcA building blocks. The oxidation state of C6 is at the carboxylic acid level in GlcA, as opposed to the primary alcohol in a pyranose. A variety of oxidation methods have been utilised to access this, with 2,2,6,6-tetramethyl-1-piperidinyloxyl/(diacetoxyiodo)benzene (TEMPO/BAIB) being frequently employed in carbohydrate syntheses due to its scalability, mild conditions and selectivity for primary alcohols [9,10]. Esterification of the uronic acid to form a uronate is desirable to protect the acid and enable facile purification [11]. Herein, we report multigram access to the title compounds, methyl- and benzyl-uronates 4 and 5, from known intermediate 2 [12], providing our record of their synthesis and full characterisation.

2. Results

Compound 2 was prepared in 42% yield over six steps from commercially available 1,2,3,4,6-penta-O-acetyl-β-D-glucose 1 according to literature procedures [12,13]. The 4,6-O-benzylidene acetal protection enabled a regioselective reductive ring opening using BH3.THF and TMSOTf to provide access to compound 3 in 91% yield, containing a free C6 hydroxyl group for oxidation (Scheme 1). The 1H and 13C NMR data agreed with previously published results [13], however, additional 2D NMR (COSY, HSQC, HMBC) and HRMS data were collected to fully characterise compound 3. The COSY NMR displayed a correlation between a broad singlet at δ 1.97 ppm and H6 environments at δ 3.93 and 3.72 ppm, indicative of C6-OH. The resultant primary alcohol 3 was next oxidised using TEMPO/BAIB. The resultant uronic acid was identified by a doublet for H5 at δ 4.08 ppm with a large JH4H5 coupling of 9.1 Hz. Subsequent esterification with either MeI or BnBr afforded the target GlcA building blocks 4 and 5 in 65% and 58% yields, respectively. Full characterisation was obtained for both compounds. HRMS data confirmed sulphur oxidation did not occur under these conditions. The analytical data collected for 4 and 5 supported the structural assignment and gave an indicative level of purity. Copies of NMR and MS data are included in the Supplementary Materials.

3. Materials and Methods

3.1. General

Unless otherwise stated, all reagents used in the following experiments were bought commercially from Acros Organics (Antwerp, Belgium), Apollo Scientific (Manchester, UK), Fisher Scientific (Loughborough, UK), Fluorochem (Manchester, UK) or Sigma Aldrich (Gillingham, UK) and were used without further purification. Dry solvents were dried and stored under N2 in Young’s flasks over 4 Å molecular sieves. Anhydrous DMF was purchased from Acros Organics (Antwerp, Belgium), fitted with AcroSeal™ packaging. Reactions were monitored by thin layer chromatography (TLC) using pre-coated 0.25 mm 60 F254 silica gel plates (Merck, London, UK) and eluent systems outlined in the respective experiments. Visualisation was achieved using UV light (λ = 254 nm) and 10% H2SO4:EtOH, followed by heating. Flash column chromatography was performed using silica gel [high purity grade, 60 Å pore size, 40–63 μm particle size]. 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra at 101 MHz on a Bruker AVIII400 spectrometer using deuterated solvent. Chemical shifts are reported in parts per million (ppm), coupling constants (J) are reported in hertz (Hz) and multiplicities are abbreviated as s (singlet), d (doublet), t (triplet) or m (multiplet) or combinations thereof. Chemical shifts were referenced to tetramethylsilane (TMS, where δ = 0.00 ppm). HRMS were recorded on a ThermoScientific LTQ Orbitrap XL at the ESPRC National Mass Spectrometry Facility at Swansea University. Infra-red spectra were recorded on a ThermoScientific Nicolet iS10 spectrometer; selected absorption frequencies (vmax) are reported in cm−1. Relative intensities are described as follows: w (weak), m (medium) and s (strong). Melting points were recorded using open glass capillaries on a Gallenkamp melting point apparatus and are uncorrected. Optical rotations were recorded on a Bellingham + Stanley ADP430 (specific rotation, tube length: 50 mm, concentrations in g per 100 mL).

3.2. Ethyl 3,4-O-benzyl-2-O-benzoyl-1-thio-β-D-glucopyranoside (3)

Under an atmosphere of N2, compound 2 (8.0 g, 15.6 mmol, 1.0 equiv.) was dissolved in DCM (60 mL) and cooled to 0 °C. A solution of 1 M BH3.THF (31 mL, 31.2 mmol, 2.0 equiv.) was added, followed by TMSOTf (0.4 mL, 2.34 mmol, 0.15 equiv.). The reaction was warmed to RT and stirred for 4 h, then cooled to 0 °C and quenched with sequential additions of Et3N (2.4 mL, 17.2 mmol, 1.1 equiv.) and MeOH (2.5 mL, 546 mmol, 35 equiv.) until effervescence stopped. The resultant mixture was concentrated in vacuo, followed by co-evaporation with MeOH (100 mL). Purification via flash column chromatography (10:1 → 7:1 → 4:1 hexane:EtOAc) afforded 3 (7.2 g, 14.2 mmol, 91%) as a white solid. Rf 0.48 (2:1, hexane:EtOAc). m.p. 84–85 °C. 1H NMR (400 MHz, CDCl3) δ 8.05–8.01 (m, 2H, Ar-H), 7.61–7.55 (m, 1H, Ar-H), 7.45 (dd, J = 10.7, 4.7 Hz, 2H, Ar-H), 7.38–7.29 (m, 5H, Ar-H), 7.17–7.11 (m, 5H, Ar-H), 5.28 (dd, J = 9.9, 9.2 Hz, 1H, H2), 4.87 (d, J = 11.0 Hz, 1H, CH2OBn), 4.76 (d, J = 11.0 Hz, 1H, CH2OBn), 4.68 (d, J = 11.0 Hz, 2H, CH2OBn), 4.58 (d, J = 10.0 Hz, 1H, H1), 3.92 (d, J = 12.1 Hz, 1H, H6a), 3.87 (t, J = 9.0 Hz, 1H, H3), 3.76–3.73 (m, 1H, H6b), 3.71 (t, J = 9.4 Hz, H4), 3.49 (ddd, J = 9.7, 4.7, 2.6 Hz, 1H, H5), 2.75–2.67 (m, 2H, SCH2CH3), 1.97 (br s, 1H, C6-OH), 1.25 (m, 3H, SCH2CH3). 13C NMR (101 MHz, CDCl3) δ 165.3 (C=O), 137.8 (Ar-C), 137.7 (Ar-C), 133.2 (Ar-C), 129.9 (Ar-CH), 129.7 (Ar-CH), 128.6 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 127.7 (Ar-CH), 127.6 (Ar-CH), 84.2 (C1), 83.8 (C3), 79.8 (C5), 77.7 (C4), 75.3 (PhCH2), 75.2 (PhCH2), 72.5 (C2), 62.1 (C6), 24.2 (SCH2CH3), 14.9 (SCH2CH3). HRMS m/z (ESI+) found (M + NH4)+ 526.2258, C29H36NO6S required (M + NH4)+, 526.2258. IR(FTIR) 3302 (s), 1693 (s), 1537 (s), 1242 (s), 1151 (m), 974 (m), 742 (m), 658 (s) cm−1. These data are consistent with the literature data [13].

3.3. Methyl (Ethyl 3,4-O-benzyl-2-O-benzoyl-1-thio-β-D-glucopyranoside)uronate (4)

To a vigorously stirred solution of 3 (6.00 g, 11.8 mmol, 1.0 equiv.) in DCM:H2O (2:1 v/v, 30 mL), TEMPO (368 mg, 2.36 mmol, 0.2 equiv.) and BAIB (9.60 g, 29.6 mmol, 2.5 equiv.) were added at 0 °C. After 10 min., the solution was warmed to RT and stirred for a further 2 h. TLC analysis showed the formation of the desired product (7:1:1, EtOAc:MeOH:H2O). The reaction was quenched with sat. aq. Na2S2O3 (20 mL), and the layers were separated. The pH of the aqueous phase was reduced to 2 with 1 M HCl, then extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was then suspended in anhydrous DMF (30 mL) under an atmosphere of N2. At 0 °C, MeI (2.20 mL, 35.4 mmol, 3.0 equiv.) and K2CO3 (4.90 g, 35.4 mmol, 3.0 equiv.) were added. The reaction was stirred at RT in the dark for 2 h before dilution with EtOAc (40 mL) and washed with H2O (2 × 30 mL) and brine (1 × 30 mL). The organic phase was dried (MgSO4), filtered and concentrated in vacuo. Purification via flash column chromatography (10:1 → 7:1 hexane:EtOAc) afforded 4 as a white solid (4.07 g, 7.55 mmol, 64% over two steps). Rf 0.60 (2:1 hexane:EtOAc). [ α ] D 24 = +25.4 (c 1, CHCl3). m.p. 108–109 °C. 1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 8.4, 1.4 Hz, 2H, Ar-H), 7.60–7.56 (m, 1H, Ar-H), 7.45 (dd, J = 8.3, 7.2 Hz, 5H, Ar-H), 7.34–7.29 (m, 5H, Ar-H), 7.13 (d, J = 1.4 Hz, 3H, Ar-H), 5.34 (dd, J = 10.0, 9.0 Hz, 1H, H2), 4.78–4.64 (m, 5H, 2 × CH2OBn, H1), 4.03–3.95 (m, 2H, H4, H5), 3.88–3.83 (t, J = 8.9 Hz, 1H, H3), 3.74 (s, 3H, OCH3), 2.80–2.66 (m, 2H, SCH2CH3), 1.22 (t, J = 7.5 Hz, 3H, SCH2CH3). 13C NMR (101 MHz, CDCl3) δ 168.4 (C=O), 165.2 (C=O), 137.7 (Ar-C), 137.5 (Ar-C), 133.2 (Ar-C), 129.8 (Ar-CH), 129.7 (Ar-CH), 128.4 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 128.1 (Ar-CH), 128.0 (Ar-CH), 128.0 (Ar-CH), 127.8 (Ar-CH), 84.2 (C1), 83.4 (C3), 79.3 (C4), 78.4 (C5), 75.3 (PhCH2), 75.2 (PhCH2), 71.9 (C2), 52.6 (OCH3), 23.9 (SCH2CH3), 14.7 (SCH2CH3). HRMS m/z (ESI+) found (M + NH4)+ 554.2206, C30H36NO7S required (M + NH4)+ 554.2207. IR(FTIR) 1720 (m), 1714 (s), 1263 (m), 1066 (m), 1024 (w), 734 (m), 694 (m) cm−1.

3.4. Benzyl (Ethyl 3,4-O-benzyl-2-O-benzoyl-1-thio-β-D-glucopyranoside)uronate (5)

To a vigorously stirred solution of 3 (2.00 g, 3.94 mmol, 1.0 equiv.) in DCM:H2O (2:1 v/v, 20 mL), TEMPO (62 mg, 0.79 mmol, 0.2 equiv.) and BAIB (3.18 g, 9.86 mmol, 2.5 equiv.) were added at 0 °C. After 10 min., the solution was warmed to RT and stirred for a further 2 h. TLC analysis showed the formation of the desired product (7:1:1, EtOAc:MeOH:H2O). The reaction was quenched with sat. aq. Na2S2O3 (20 mL), and the layers were separated. The pH of the aqueous phase was tuned to pH 2 with 1 M HCl, then extracted with EtOAc (3 × 30 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude material was then suspended in anhydrous DMF (13 mL) under an atmosphere of N2. At 0 °C, BnBr (0.70 mL, 5.92 mmol, 1.5 equiv.) and K2CO3 (820 mg, 5.92 mmol, 1.5 equiv.) were added. The reaction was stirred at RT for 18 h before dilution with EtOAc (25 mL) and washing with H2O (3 × 30 mL). The organic phase was dried (MgSO4), filtered and concentrated in vacuo. Purification via flash column chromatography (10/1 → 7/1 EtOAc/hexane) afforded 5 as a white solid (1.4 g, 2.23 mmol, 58%). Rf 0.63 (2/1, EtOAc/hexane). [ α ] D 20 = +13.4 (c 1, CHCl3). m.p. 106–107 °C. 1H NMR (400 MHz, CDCl3) δ 8.04–7.97 (m, 2H, Ar-H), 7.57 (ddt, J = 8.7, 7.0, 1.4 Hz, 1H, Ar-H), 7.43 (dd, J = 8.3, 7.1 Hz, 2H, Ar-H), 7.38–7.22 (m, 8H, Ar-H), 7.11 (ddt, J = 7.4, 5.2, 3.8 Hz, 7H, Ar-H), 5.34 (dd, J = 10.0, 9.0 Hz, 1H, H2), 5.19 (s, 2H, 2 × CH2-OBn) 4.72 (dd, J = 11.0, 1.5 Hz, 2H, 2 × CH2-OBn), 4.64 (d, J = 11.1 Hz, 1H, CH2-OBn), 4.58 (d, J = 10.0 Hz, 1H, H1), 4.49 (d, J = 10.7 Hz, 1H, CH2), 4.06–3.95 (m, 2H, H4, H5), 3.84 (t, J = 8.8 Hz, 1H, H3), 2.80–2.63 (m, 2H, SCH2CH3), 1.21 (t, J = 7.5 Hz, 3H, SCH2CH3). 13C NMR (101 MHz, CDCl3) δ 167.8 (C=O), 165.1 (C=O), 137.6 (Ar-C), 137.5 (Ar-C), 135.0 (Ar-C), 133.2 (Ar-C), 129.8 (Ar-CH), 129.7 (Ar-CH), 128.6 (Ar-CH), 128.6 (Ar-CH), 128.5 (Ar-CH), 128.5 (Ar-CH), 128.4 (Ar-CH), 128.4 (Ar-CH), 128.3 (Ar-CH), 127.9 (Ar-CH), 127.8 (Ar-CH), 127.8 (Ar-CH), 84.2 (C1), 83.3 (C3), 79.4 (C4), 78.5 (C5), 75.3 (CH2-OBn), 75.1 (CH2-OBn), 71.8 (C2), 67.4 (CH2-OBn), 23.9 (SCH2CH3), 14.8 (SCH2CH3). HRMS m/z (ES+) found (M + NH4)+ 630.2517, C36H40NO7S requires (M + NH4)+, 630.2520. IR(FTIR) 1724 (m), 1718 (s), 1257 (m), 1170 (s), 1072 (s), 750 (m), 694 (s) cm−1.

Supplementary Materials

The following pages contain representative spectral characterisation data, including NMR, HRMS and IR for (3), (4) and (5).

Author Contributions

G.J.M. and H.S.W. conceived and designed the experiments; H.S.W. performed the experiments and analysed the data; and H.S.W. and G.J.M. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

G.J.M. thanks UK Research and Innovation (Future Leaders Fellowship, MR/T019522/1) for project grant funding. Keele University are thanked for funding to H.S.W.

Data Availability Statement

The original contributions presented in the study are included in the Supplementary Materials, further inquiries can be directed to the corresponding author.

Acknowledgments

The EPSRC UK National Mass Spectrometry Facility (NMSF) at Swansea University is thanked for MS analyses.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Pongener, I.; O’Shea, C.; Wootton, H.S.; Watkinson, M.; Miller, G.J. Developments in the Chemical Synthesis of Heparin and Heparan Sulfate. Chem. Rec. 2021, 21, 3238–3255. [Google Scholar] [CrossRef] [PubMed]
  2. Mende, M.; Bednarek, C.; Wawryszyn, M.; Sauter, P.; Biskup, M.B.; Schepers, U.; Bräse, S. Chemical Synthesis of Glycosaminoglycans. Chem. Rev. 2016, 116, 8193–8255. [Google Scholar] [CrossRef] [PubMed]
  3. Perez, S.; Makshakova, O.; Angulo, J.; Bedini, E.; Bisio, A.; de Paz, J.L.; Fadda, E.; Guerrini, M.; Hricovini, M.; Lisacek, F.; et al. Glycosaminoglycans: What Remains to Be Deciphered? J. Am. Chem. Soc. Au 2023, 3, 628–656. [Google Scholar] [CrossRef] [PubMed]
  4. Pongener, I.; Miller, G.J. D-Glucuronate and D-Glucuronate Glycal Acceptors for the Scalable Synthesis of D-GlcN-α-1,4-D-GlcA Disaccharides and Modular Assembly of Heparan Sulfate. J. Org. Chem. 2023, 88, 11130–11139. [Google Scholar] [CrossRef] [PubMed]
  5. Pongener, I.; Sletten, E.T.; Danglad-Flores, J.; Seeberger, P.H.; Miller, G.J. Synthesis of a heparan sulfate tetrasaccharide using automated glycan assembly. Org. Biomol. Chem. 2024, 22, 1395–1399. [Google Scholar] [CrossRef] [PubMed]
  6. Meneghetti, M.C.Z.; Naughton, L.; O’shea, C.; Koffi Teki, D.S.E.; Chagnault, V.; Nader, H.B.; Rudd, T.R.; Yates, E.A.; Kovensky, J.; Miller, G.J.; et al. Using NMR to Dissect the Chemical Space and O-Sulfation Effects within the O- A nd S-Glycoside Analogues of Heparan Sulfate. ACS Omega 2022, 7, 24461–24467. [Google Scholar] [CrossRef] [PubMed]
  7. Baráth, M.; Hansen, S.U.; Dalton, C.E.; Jayson, G.C.; Miller, G.J.; Gardiner, J.M. Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential O-6 protections: Programming for regiodefined 6-O-modifications. Molecules 2015, 20, 6167–6180. [Google Scholar] [CrossRef] [PubMed]
  8. Mycroft-West, C.J.; Devlin, A.J.; Cooper, L.C.; Procter, P.; Miller, G.J.; Fernig, D.G.; Guerrini, M.; Guimond, S.E.; Lima, M.A.; Yates, E.A.; et al. Inhibition of BACE1, the β-secretase implicated in Alzheimer’s disease, by a chondroitin sulfate extract from Sardina pilchardus. Neural Regen. Res. 2020, 15, 1546–1553. [Google Scholar] [PubMed]
  9. Van Den Bos, L.J.; Codée, J.D.C.; Van Der Toorn, J.C.; Boltje, T.J.; Van Boom, J.H.; Overkleeft, H.S.; Van Der Marel, G.A. Thioglycuronides: Synthesis and Application in the Assembly of Acidic Oligosaccharides. Org. Lett. 2004, 6, 2165–2168. [Google Scholar] [CrossRef] [PubMed]
  10. De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. A Versatile and Highly Selective Hypervalent Iodine (III)/2,2,6,6-Tetramethyl-1-piperidinyloxyl-Mediated Oxidation of Alcohols to Carbonyl Compounds. J. Org. Chem. 1997, 62, 6974–6977. [Google Scholar] [CrossRef]
  11. Van Den Bos, L.J.; Codée, J.D.C.; Litjens, R.E.J.N.; Dinkelaar, J.; Overkleeft, H.S.; Van Der Marel, G.A. Uronic acids in oligosaccharide synthesis. Eur. J. Org. Chem. 2007, 24, 3963–3976. [Google Scholar] [CrossRef]
  12. Zhu, Y.; Tyrikos-Ergas, T.; Schiefelbein, K.; Grafmüller, A.; Seeberger, P.H.; Delbianco, M. Automated access to well-defined ionic oligosaccharides. Org. Biomol. Chem. 2020, 18, 1349–1353. [Google Scholar] [CrossRef] [PubMed]
  13. Daragics, K.; Fügedi, P. Synthesis of glycosaminoglycan oligosaccharides. Part 5: Synthesis of a putative heparan sulfate tetrasaccharide antigen involved in prion diseases. Tetrahedron 2010, 66, 8036–8046. [Google Scholar] [CrossRef]
Scheme 1. Synthesis of methyl and benzyl glucuronates 4 and 5 from peracetylated glucose 1.
Scheme 1. Synthesis of methyl and benzyl glucuronates 4 and 5 from peracetylated glucose 1.
Molbank 2024 m1847 sch001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wootton, H.S.; Miller, G.J. Methyl and Benzyl (Ethyl 3,4-di-O-benzyl-2-O-benzoyl-1-thio-β-d-glucopyranosyl)uronate. Molbank 2024, 2024, M1847. https://doi.org/10.3390/M1847

AMA Style

Wootton HS, Miller GJ. Methyl and Benzyl (Ethyl 3,4-di-O-benzyl-2-O-benzoyl-1-thio-β-d-glucopyranosyl)uronate. Molbank. 2024; 2024(3):M1847. https://doi.org/10.3390/M1847

Chicago/Turabian Style

Wootton, Hannah S., and Gavin J. Miller. 2024. "Methyl and Benzyl (Ethyl 3,4-di-O-benzyl-2-O-benzoyl-1-thio-β-d-glucopyranosyl)uronate" Molbank 2024, no. 3: M1847. https://doi.org/10.3390/M1847

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop